Pharmacodynamic Effects of Riociguat in Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 118 participants.
Also called NCT02744339
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 118 participants
- Sponsor
- Registry
-
NCT02744339 -
2014-003055-60
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Austria
- Registry status
- Completed
Technical summary
Registry record NCT02744339. Randomized; double masking; primary purpose treatment. Start 2016-03 (actual); primary completion 2020-08 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Pharmacodynamic Effects of Riociguat in Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction
- Acronym
- DYNAMIC
- Condition
- Hypertension, Pulmonary
- Condition
- Heart Failure With Normal Ejection Fraction
- Intervention (Drug)
- Riociguat
- Intervention (Drug)
- Placebo
- Lead sponsor
- Medical University of Vienna
Record details
- Record id
cardio:ct-nct02744339- Content hash
332b8ac6f3ac18cca7fcd144253755d8e53797bcf1d6f34b705057aec66f26b9